NEOGENOMICS INC — Director's Dealing 2017

May 30, 2017

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: NEOGENOMICS INC (NEO)
CIK: 0001077183
Period of Report: 2016-05-25

Reporting Person: ALBITAR MAHER (Chief Medical Officer)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2017-05-25	Restricted Stock	$0.00	A	20000	Acquired		Common Stock (20000)	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	60692	Indirect

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Stock Option (Right to Buy)	$7.15	2021-04-20	Common Stock (200000)	200000	Direct
Stock Option (Right to Buy)	$7.52	2022-04-28	Common Stock (200000)	200000	Direct

Footnotes

F1: On April 20, 2016, Dr. Albitar was granted 200,000 stock options. These options vest ratably over the first three anniversary dates of the grant date.

F2: On April 28, 2017, Dr. Albitar was granted 200,000 stock options. The options vest ratably over the first three anniversary dates of the grant date.

F3: Each restricted stock unit represents the contingent right to receive one share of common stock upon vesting of the unit.

F4: Restricted stock will vest as follows; 6,666 will vest on May 25, 2018 and 6,667 will vest on May 25, 2019 and 2020.

F5: These restricted stock units will terminate upon the earliest of death, termination of employment or the last vesting date.